Corcept Therapeutics Incorporated (NASDAQ: CORT) Stock Competitors & Peer Comparison

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, RPRX has a market cap of 27.2B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while RPRX trades at $61.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas RPRX's P/E ratio is 11.68. In terms of profitability, CORT's ROE is +0.08%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CORT is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check RPRX's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas WBA's P/E ratio is -1.64. In terms of profitability, CORT's ROE is +0.08%, compared to WBA's ROE of -0.42%. Regarding short-term risk, CORT is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check WBA's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, LQDA has a market cap of 6.1B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while LQDA trades at $68.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas LQDA's P/E ratio is 490.14. In terms of profitability, CORT's ROE is +0.08%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CORT is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for CORT.Check LQDA's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while KNSA trades at $79.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas KNSA's P/E ratio is 87.81. In terms of profitability, CORT's ROE is +0.08%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CORT is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CORT.Check KNSA's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while PBH trades at $51.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas PBH's P/E ratio is 11.61. In terms of profitability, CORT's ROE is +0.08%, compared to PBH's ROE of +0.09%. Regarding short-term risk, CORT is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for CORT.Check PBH's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas HROWL's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CORT is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CORT.Check HROWL's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while LTGO trades at $22.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas LTGO's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to LTGO's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CORT.Check LTGO's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas HROWM's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CORT is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CORT.Check HROWM's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, HELP has a market cap of 780.4M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while HELP trades at $12.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas HELP's P/E ratio is -3.02. In terms of profitability, CORT's ROE is +0.08%, compared to HELP's ROE of -0.71%. Regarding short-term risk, CORT is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CORT.Check HELP's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas SVA's P/E ratio is -5.68. In terms of profitability, CORT's ROE is +0.08%, compared to SVA's ROE of -0.01%. Regarding short-term risk, CORT is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SVA's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, CUVL has a market cap of 390.3M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while CUVL trades at $7.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas CUVL's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CUVL's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CUVL's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, HITI has a market cap of 215.3M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while HITI trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas HITI's P/E ratio is 61.25. In terms of profitability, CORT's ROE is +0.08%, compared to HITI's ROE of -0.43%. Regarding short-term risk, CORT is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for CORT.Check HITI's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CELG-RI's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CORT's ROE is +0.08%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CORT is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ATLN's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while CTOR trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas CTOR's P/E ratio is -1.62. In terms of profitability, CORT's ROE is +0.08%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CORT is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CTOR's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, SDEV has a market cap of 57M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while SDEV trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas SDEV's P/E ratio is -0.20. In terms of profitability, CORT's ROE is +0.08%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CORT is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SDEV's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas RAD's P/E ratio is -0.05. In terms of profitability, CORT's ROE is +0.08%, compared to RAD's ROE of +2.76%. Regarding short-term risk, CORT is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CORT.Check RAD's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CORT's ROE is +0.08%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CORT is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CORT.Check GLTO's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, NSRX has a market cap of 34.5M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while NSRX trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas NSRX's P/E ratio is -5.56. In terms of profitability, CORT's ROE is +0.08%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, CORT is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check NSRX's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, SCYX has a market cap of 32.1M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while SCYX trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas SCYX's P/E ratio is -1.49. In terms of profitability, CORT's ROE is +0.08%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CORT is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SCYX's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, CNSY has a market cap of 20.6M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while CNSY trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas CNSY's P/E ratio is -0.42. In terms of profitability, CORT's ROE is +0.08%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CORT is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CNSY's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, BFRI has a market cap of 18.9M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while BFRI trades at $1.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas BFRI's P/E ratio is -2.69. In terms of profitability, CORT's ROE is +0.08%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CORT is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CORT.Check BFRI's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, BFRIW has a market cap of 16.7M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, CORT's ROE is +0.08%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CORT is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CORT.Check BFRIW's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, COSM has a market cap of 11.6M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas COSM's P/E ratio is -0.29. In terms of profitability, CORT's ROE is +0.08%, compared to COSM's ROE of -1.19%. Regarding short-term risk, CORT is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CORT.Check COSM's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CORT's ROE is +0.08%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CORT is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CJJD's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas SSY's P/E ratio is -2.86. In terms of profitability, CORT's ROE is +0.08%, compared to SSY's ROE of -0.09%. Regarding short-term risk, CORT is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SSY's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, POM has a market cap of 6.5M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while POM trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas POM's P/E ratio is -0.19. In terms of profitability, CORT's ROE is +0.08%, compared to POM's ROE of +0.16%. Regarding short-term risk, CORT is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CORT.Check POM's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while BGMS trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas BGMS's P/E ratio is -0.25. In terms of profitability, CORT's ROE is +0.08%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CORT is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CORT.Check BGMS's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, PAVS has a market cap of 4.3M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while PAVS trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas PAVS's P/E ratio is -0.06. In terms of profitability, CORT's ROE is +0.08%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CORT is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CORT.Check PAVS's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CORT's ROE is +0.08%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CORT is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CORT.Check MDVL's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CORT is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ATNFW's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CORT's ROE is +0.08%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CORT is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CORT.Check BGMSP's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CORT's ROE is +0.08%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CORT is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CORT.Check AZNH's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, PRPH has a market cap of 346.2K. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while PRPH trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas PRPH's P/E ratio is -0.01. In terms of profitability, CORT's ROE is +0.08%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CORT is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CORT.Check PRPH's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CORT's ROE is +0.08%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CORT is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CORT.Check LFLYW's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CORT's ROE is +0.08%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CORT is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check ESRX's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, CPD has a market cap of 0. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas CPD's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CPD's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CPD's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, OREX has a market cap of 0. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas OREX's P/E ratio is -0.14. In terms of profitability, CORT's ROE is +0.08%, compared to OREX's ROE of -0.54%. Regarding short-term risk, CORT is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check OREX's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, POZN has a market cap of 0. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas POZN's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to POZN's ROE of +0.61%. Regarding short-term risk, CORT is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check POZN's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CORT's ROE is +0.08%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CORT is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CORT.Check IPXL's competition here

Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CORT stands at 13.1B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CORT is priced at $122.25 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CORT currently has a P/E ratio of 345.86, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CORT's ROE is +0.08%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CORT is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SHPG's competition here